FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2149296823> ?p ?o ?g. }

• W2149296823 endingPage "2471" @default.
• W2149296823 startingPage "2464" @default.
• W2149296823 abstract "This phase II trial evaluated the effect of neoadjuvant chemotherapy with or without second-look surgery before craniospinal irradiation on response rates and survival outcomes in children with newly diagnosed non-germinomatous germ cell tumors.Induction chemotherapy consisted of six cycles of carboplatin/etoposide alternating with ifosfamide/etoposide. Patients demonstrating less than complete response after induction chemotherapy were encouraged to undergo second-look surgery. Patients who did not achieve complete response or partial response after chemotherapy with or without second-look surgery proceeded to high-dose chemotherapy with thiotepa and etoposide and autologous peripheral blood stem-cell rescue before craniospinal irradiation.The study included 102 patients treated between January 2004 and July 2008. Median age was 12 years, and 76% were male; 53.9% had pineal region masses, and 23.5% had suprasellar lesions. Sixty-nine percent of patients achieved complete response or partial response with neoadjuvant chemotherapy. At 5 years, event-free survival was 84% ± 4% (SE) and overall survival was 93% ± 3%. During the median follow-up of 5.1 years, 16 patients recurred or progressed, with seven deaths after relapse. No deaths were attributed to therapy-related toxicity. Relapse occurred at the site of primary disease in 10 patients, at a distant site in three patients, or both in one patient. In two patients, progression was detected by marker increase alone. Increased serum α-fetoprotein was a negative prognostic variable. Histologic subtype and increase of beta-human chorionic gonadotropin were not significantly correlated with worse outcomes.Neoadjuvant chemotherapy with or without second-look surgery achieved high response rates contributing to excellent survival outcomes in children with newly diagnosed non-germinomatous germ cell tumors. This regimen should be included as a backbone for further studies." @default.
• W2149296823 created "2016-06-24" @default.
• W2149296823 creator A5001092978 @default.
• W2149296823 creator A5002452432 @default.
• W2149296823 creator A5010948664 @default.
• W2149296823 creator A5060210860 @default.
• W2149296823 creator A5068257880 @default.
• W2149296823 creator A5071378074 @default.
• W2149296823 creator A5073294664 @default.
• W2149296823 creator A5076968637 @default.
• W2149296823 creator A5080784534 @default.
• W2149296823 creator A5083585208 @default.
• W2149296823 creator A5084993379 @default.
• W2149296823 date "2015-08-01" @default.
• W2149296823 modified "2023-10-16" @default.
• W2149296823 title "Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study" @default.
• W2149296823 cites W1518555411 @default.
• W2149296823 cites W168729159 @default.
• W2149296823 cites W1861752925 @default.
• W2149296823 cites W1965779893 @default.
• W2149296823 cites W1966005817 @default.
• W2149296823 cites W1966518084 @default.
• W2149296823 cites W2000056119 @default.
• W2149296823 cites W2007208661 @default.
• W2149296823 cites W2022735264 @default.
• W2149296823 cites W2025846087 @default.
• W2149296823 cites W2040873764 @default.
• W2149296823 cites W2043536578 @default.
• W2149296823 cites W2075910427 @default.
• W2149296823 cites W2076172260 @default.
• W2149296823 cites W2076408368 @default.
• W2149296823 cites W2101281476 @default.
• W2149296823 cites W2108795808 @default.
• W2149296823 cites W2110391100 @default.
• W2149296823 cites W2112209835 @default.
• W2149296823 cites W2120232887 @default.
• W2149296823 cites W2138204078 @default.
• W2149296823 cites W2141783551 @default.
• W2149296823 cites W2144589754 @default.
• W2149296823 cites W2162629228 @default.
• W2149296823 cites W2164674797 @default.
• W2149296823 cites W2215118042 @default.
• W2149296823 cites W96113596 @default.
• W2149296823 doi "https://doi.org/10.1200/jco.2014.59.5132" @default.
• W2149296823 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4507465" @default.
• W2149296823 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26101244" @default.
• W2149296823 hasPublicationYear "2015" @default.
• W2149296823 type Work @default.
• W2149296823 sameAs 2149296823 @default.
• W2149296823 citedByCount "122" @default.
• W2149296823 countsByYear W21492968232016 @default.
• W2149296823 countsByYear W21492968232017 @default.
• W2149296823 countsByYear W21492968232018 @default.
• W2149296823 countsByYear W21492968232019 @default.
• W2149296823 countsByYear W21492968232020 @default.
• W2149296823 countsByYear W21492968232021 @default.
• W2149296823 countsByYear W21492968232022 @default.
• W2149296823 countsByYear W21492968232023 @default.
• W2149296823 crossrefType "journal-article" @default.
• W2149296823 hasAuthorship W2149296823A5001092978 @default.
• W2149296823 hasAuthorship W2149296823A5002452432 @default.
• W2149296823 hasAuthorship W2149296823A5010948664 @default.
• W2149296823 hasAuthorship W2149296823A5060210860 @default.
• W2149296823 hasAuthorship W2149296823A5068257880 @default.
• W2149296823 hasAuthorship W2149296823A5071378074 @default.
• W2149296823 hasAuthorship W2149296823A5073294664 @default.
• W2149296823 hasAuthorship W2149296823A5076968637 @default.
• W2149296823 hasAuthorship W2149296823A5080784534 @default.
• W2149296823 hasAuthorship W2149296823A5083585208 @default.
• W2149296823 hasAuthorship W2149296823A5084993379 @default.
• W2149296823 hasBestOaLocation W21492968232 @default.
• W2149296823 hasConcept C121608353 @default.
• W2149296823 hasConcept C126322002 @default.
• W2149296823 hasConcept C141071460 @default.
• W2149296823 hasConcept C143998085 @default.
• W2149296823 hasConcept C2776611710 @default.
• W2149296823 hasConcept C2776694085 @default.
• W2149296823 hasConcept C2776755627 @default.
• W2149296823 hasConcept C2776938808 @default.
• W2149296823 hasConcept C2777506904 @default.
• W2149296823 hasConcept C2778119113 @default.
• W2149296823 hasConcept C2778239845 @default.
• W2149296823 hasConcept C2778292576 @default.
• W2149296823 hasConcept C2778822529 @default.
• W2149296823 hasConcept C2779968505 @default.
• W2149296823 hasConcept C2781451048 @default.
• W2149296823 hasConcept C530470458 @default.
• W2149296823 hasConcept C71924100 @default.
• W2149296823 hasConceptScore W2149296823C121608353 @default.
• W2149296823 hasConceptScore W2149296823C126322002 @default.
• W2149296823 hasConceptScore W2149296823C141071460 @default.
• W2149296823 hasConceptScore W2149296823C143998085 @default.
• W2149296823 hasConceptScore W2149296823C2776611710 @default.
• W2149296823 hasConceptScore W2149296823C2776694085 @default.
• W2149296823 hasConceptScore W2149296823C2776755627 @default.
• W2149296823 hasConceptScore W2149296823C2776938808 @default.
• W2149296823 hasConceptScore W2149296823C2777506904 @default.
• W2149296823 hasConceptScore W2149296823C2778119113 @default.

• next